Thoratec boosts sales, but profits stay flat

Thanks to its banner HeartMate device, Thoratec ($THOR) handed in another quarter of solid revenue growth, but a spike in costs kept its net income from moving upward. Sales jumped 7% to $125.7 million on the quarter, with HeartMate accounting for $110 million of that figure. Despite the gains, Thoratec's profits came in at $18.2 million, exactly aligned with the first quarter of 2013. Results

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.